Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Virttu Biologics Appoints CEO

This article was originally published in Scrip

Executive Summary

Virttu Biologics, a biotechnology company focused on developing oncolytic immunotherapies, has appointed Deirdre Y. Gillespie CEO. Gillespie has experience of working with oncolytic vectors and was CEO of privately held Oxxon Therapeutics Inc. from 2001 to 2006. She was previously president and CEO of publically held La Jolla Pharmaceutical Company and chief operating officer of Vical, Inc. Gillespie also held various positions in clinical development at Sandoz Pharma AG (Novartis) and senior strategic and commercial positions at DuPont Merck Pharmaceutical Company including vice-president of marketing.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts